AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Plan to save ‘cash-strapped’ Cannasouth put forward
Primary Sector

Plan to save ‘cash-strapped’ Cannasouth put forward

The NZX-listed group went into voluntary administration in March.

Fonterra wasn’t expecting ‘strong’ consumer margins to hold up
Primary Sector

Fonterra wasn’t expecting ‘strong’ consumer margins to hold up

The consumer channel’s gross margin for the quarter was 26.5%.

Cook Strait 'fiasco' troubles Mainfreight
Infrastructure

Cook Strait 'fiasco' troubles Mainfreight

Managing director Don Braid sees roads and rail as complementary modes.

F&P Healthcare, Mainfreight gains not enough to lift NZ sharemarket
Markets Market close

F&P Healthcare, Mainfreight gains not enough to lift NZ sharemarket

The S&P/NZX 50 Index closed at 11,678.68, down 3.83 points or 0.03%.

Graham Skellern 29 May 2024